The Effect on Depressive Symptoms in ECF Residents With COPD: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for The Effect on Depressive Symptoms in ECF Residents With COPD (NCT00974246), a na phase 4 study. The primary outcome is To Determine the Effect of Treating COPD Patients With Advair Diskus for 16 Weeks on the Cornell Depression Scale or Section D SUM of the Minimum Data Set 3.0.

2. Clinical Question

3. Trial Design

The registry lists this as a Phase 4, completed, single-group study, with enrollment of 30. The intervention is Advair Diskus, described as open-label treatment in COPD patients living in an ECF, or nursing-home, setting. The study start is recorded as 2009-10 and primary completion as 2011-07. The record does not give a more detailed account of recruitment, follow-up, or the dates on which individual participants entered or completed the study.

Allocation is recorded as NA, masking as none, and the model as single group. These details mean the registry does not describe random assignment, blinding, or a concurrent comparison arm. The recorded design therefore cannot separate changes observed during treatment from changes that might have occurred over time for other reasons. In an uncontrolled study, changes may reflect the intervention, the natural course of participants’ health, other care, measurement variation, or a combination of influences. The registry record does not report procedures intended to distinguish among these possibilities.

The stated primary outcome timeframe is 16 weeks. The primary measure is described as the mean on the Cornell Depression Scale or Section D SUM of the Minimum Data Set 3.0, with a 95% confidence interval. The record includes descriptions of these scales but does not report the corresponding outcome values or explain how the two measures relate to one another in the primary analysis. It also does not report the analysis population, participant flow, or handling of incomplete measurements.

The registry marks the study completed, but completion status does not by itself establish that every planned assessment was collected or analyzed. Statistical analysis results are not reported in the registry record. In particular, a numerical change, its uncertainty, and a formal test of the primary question cannot be recovered from the information recorded for the primary outcome.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as To Determine the Effect of Treating COPD Patients With Advair Diskus for 16 Weeks on the Cornell Depression Scale or Section D SUM of the Minimum Data Set 3.0, measured over 16 weeks.

The primary outcome description names the Cornell Depression Scale and Section D SUM of the Minimum Data Set 3.0. The Cornell Depression Scale ranges from 0-38, and a score 12 points or more indicates probable depression. Section D SUM is described as an assessment tool of health status for all residents of long-term care facilities certified to participate in Medicare or Medicaid. Its scores range from 0 to 27, with a higher score indicating more depression.

These measures are relevant to the stated question because they quantify depressive symptoms or depression-related information in the nursing-home setting. The Cornell measure is explicitly described in relation to probable depression; the Section D SUM is a broader resident assessment measure. Their score ranges and interpretations are not interchangeable, so results would need to be identified by measure to be read appropriately. The registry record does not clarify whether the primary outcome was intended to use one measure, the other, or both under the wording “or.”

The endpoint is specified as a mean, with a 95% confidence interval, at 16 weeks. A mean describes the average score in the analyzed group; a confidence interval conveys uncertainty around an estimate. However, the registry record does not report the primary mean, any baseline or follow-up score, a change estimate, or a confidence interval. It is therefore not possible to judge the observed score level or its precision from the recorded results.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes the primary outcome as a continuous measure summarized by a mean and 95% confidence interval. The following statistical concepts are general explanations of those methods; they do not substitute for analysis details or results that are not reported in the registry record.

What does a mean describe?

A mean is an average of the measured scores in the group being analyzed. For a continuous scale, it can provide a compact description of the group’s score level. The interpretation depends on which measure is being summarized, what time point the scores represent, and which participants are included. Here, the outcome title refers to the Cornell Depression Scale or Section D SUM of the Minimum Data Set 3.0, and the timeframe is 16 weeks. The registry record does not report the mean or specify which measure’s value was analyzed as the primary result.

If the scientific question concerns change, a mean at follow-up alone is not enough to show change from baseline. A change estimate requires scores at relevant time points or a model that estimates change. The record does not report a baseline score, a follow-up score, or a change estimate. It also does not describe an adjustment model. No such analysis should be inferred from the stated summary format.

How should a confidence interval be read?

A confidence interval expresses uncertainty around an estimated quantity under the statistical method used. It is not a guarantee that the true value lies within the particular interval, and it does not by itself establish clinical importance or causation. A 95% confidence interval is listed as the dispersion measure for the primary continuous outcome. The interval’s endpoints are not reported in the registry record, so its width and the precision of the estimate cannot be evaluated.

A confidence interval can also help distinguish a precise estimate from one that remains compatible with a broad range of values. That interpretation requires the actual estimate, its interval, the scale’s meaning, and a clear statement of whether the estimate is a score, difference, or change. Those result details are not reported in the registry record. The confidence level alone does not show whether a treatment-related effect was large, small, positive, or negative.

Why does the single-group design matter?

In general, a concurrent comparison group helps account for changes that would occur over time even without the intervention. In a single-group design, observed change can reflect treatment as well as background trends, co-interventions, changes in health, or measurement variability. This is a design limitation when the aim is to attribute an observed change to treatment. The registry records a single-group model, allocation as NA, and no masking; it does not describe a control group or random allocation.

Open-label status means masking is recorded as none. In general, knowledge of treatment can affect participant reports, care decisions, and outcome assessment, depending on how measurements are collected. The record does not report who assessed the scales or whether assessment procedures were standardized. It would be unwarranted to assume either that these influences occurred or that they were prevented.

What do over-dispersion and distributional assumptions mean?

For count outcomes, over-dispersion means variability exceeds what a simple count model expects, and a model that ignores it can understate uncertainty. This is a general concept, but the primary outcome in this study is described as a continuous mean, not a count. The registry record does not report a statistical model or distributional assumptions for the primary analysis. It is therefore not appropriate to claim that a particular model was used or that over-dispersion was assessed.

More generally, continuous-score analysis may depend on the score distribution, repeated measurements, and the way missing observations are handled. Methods can include direct comparisons of averages or models that account for measurement timing and other covariates. These are examples of possible approaches, not descriptions of this study’s analysis. The registry record does not report an analysis plan or results of statistical checks.

How should planning calculations be understood?

Sample-size calculations are planning tools. They describe how many participants per arm might be needed under stated assumptions to detect a specified effect with a chosen error rate and power. They are not observed evidence that an effect exists and are not “observed power.” The planning assumptions associated with this record describe a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect set as a stated fraction of the observed effect. The record also distinguishes participant-per-arm calculations from total event calculations for time-to-event outcomes.

Those assumptions are for a planning illustration, not a description of the trial’s own design. This study is recorded as single group, and the record does not report the trial’s sample-size justification or its analysis plan. Numerical planning results are not described in the available record details. They should not be treated as evidence about the study’s observed effect or as proof of the precision of its primary outcome.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists three outcome measures, while the primary outcome title refers to the Cornell Depression Scale or Section D SUM of the Minimum Data Set 3.0. It does not report how the primary measure was selected, whether the listed measures were treated as separate tests, or whether any adjustment for multiple comparisons was planned. The multiplicity strategy is not reported in the registry record.

Multiplicity matters in general when several outcomes, time points, or analyses are examined, because the chance of at least one apparently notable result can increase with the number of opportunities to test. Statistical approaches can address this issue, but no particular approach can be attributed to this study from the recorded information. The record also reports no analyses, so there are no posted analysis results from which to assess how outcome selection or multiple testing affected interpretation.

Missing-data procedures and analysis populations are not reported in the registry record. The enrollment figure does not establish how many participants contributed primary endpoint observations, and the record does not provide participant flow, reasons for missing measurements, or a definition of the analyzed population. It also does not say whether the analysis included all enrolled participants or only participants with available measurements. These omissions limit assessment of possible bias from incomplete follow-up.

In general, missing-data methods rely on assumptions about why values are missing and may lead to different estimates when those assumptions differ. Without the missingness pattern and analysis approach, readers cannot evaluate whether the primary estimate may depend on those assumptions. The study’s status is completed, but completion status does not supply the missing analysis details or establish completeness of endpoint data.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: mental status change (3.7%), increased agitation with combative behaviors (3.7%), left above the knee amputation (3.7%).

The adverse-event record lists 27 participants at risk for serious adverse events and 3 affected. It lists 27 at risk for other adverse events and 27 affected. These figures describe the entries recorded in the registry; they do not, by themselves, establish how events were counted, whether a participant could have multiple events, or how the categories were defined beyond their labels. The record does not report deaths.

The listed serious adverse event terms are Mental Status Change, Increased Agitation with Combative Behaviors, and Left Above the Knee Amputation. Each is paired with 3.7% in the registry record. These entries should be read as reported safety terms and percentages, not as a complete account of every possible event or as evidence about causation. The record does not provide event narratives, timing, severity grading, or an assessment of whether events were considered related to treatment.

Safety figures in a single-group study do not offer a controlled comparison of event frequency. The registry does not describe a comparator group, and the recorded data do not support attributing an event to treatment or comparing risk with another treatment. The deaths field has no reported value, so deaths are not reported in the registry record; that should not be interpreted as evidence that none occurred. The available information is insufficient to characterize safety beyond the recorded counts and terms.

12. What the Result Does, and Does Not, Mean

The record establishes that a completed Phase 4 study examined open-label Advair Diskus treatment in nursing-home residents with COPD and assessed depression-related outcomes over 16 weeks. It specifies a single-group design and a primary endpoint described as a mean with a 95% confidence interval. It also gives descriptions of the Cornell Depression Scale and Section D SUM of the Minimum Data Set 3.0. These details explain the study’s intended question and measurement context.

The record does not report the primary outcome values, a confidence interval, or a statistical analysis. It therefore does not show whether scores changed, how large any change was, or how precisely it was estimated. It also does not report which of the two named scales posted the primary result. No conclusion about the direction, size, statistical significance, or clinical importance of an effect can be drawn from the available primary outcome information.

Even with a numerical change, a single-group design would limit causal interpretation. Change during treatment is not the same as change caused by treatment; without a concurrent comparison, other explanations cannot be ruled out on the basis of the design described in the registry. The record does not provide additional analysis details that would resolve this limitation.

Likewise, enrollment of 30 does not indicate how many participants completed the 16-week assessment or contributed to analysis. The analysis population and missing-data handling are not reported. The safety entries provide recorded counts and terms, but no comparator, event timing, or causality assessments are reported. These limitations mean the record is useful for identifying the study design and outcomes of interest, but it does not provide enough result information to estimate benefit or harm or to support a treatment recommendation.

13. Why This Trial Matters Statistically

This study is statistically notable because the stated clinical question concerns depression in COPD patients in a nursing-home setting, while the registry describes a single-group, open-label design. The design is important to interpreting any change in a measured score: without a concurrent comparison, the observed course cannot be separated from other changes over time. That distinction is central when a study seeks to assess an intervention’s effect.

The outcome wording also deserves attention. The primary title names the Cornell Depression Scale or Section D SUM of the Minimum Data Set 3.0, which have different descriptions and score ranges. Clear reporting would identify which measure was analyzed, whether both were assessed, and how the primary result was defined. The record does not report that clarification or the outcome estimates themselves.

Precision is another key issue. A mean paired with a 95% confidence interval can communicate uncertainty, but the record does not report either the mean or the interval. Enrollment alone cannot show the precision of an endpoint estimate, especially when the number contributing outcome data and the handling of missing values are not reported.

The record thus illustrates why study status, sample enrollment, and outcome evidence are distinct. It is marked completed and identifies its intervention, population, design, and timeframe, yet the primary statistical results are not reported in the registry record. Readers can identify what was intended to be measured, but cannot evaluate the estimated change, uncertainty, or treatment attribution from the recorded information.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this study follow directly from the registry description. The design is single group, with allocation recorded as NA and masking as none. No concurrent control group is described. These features limit the ability to distinguish changes associated with treatment from changes due to time, other care, health changes, or measurement variation. The record does not report any design feature that would address those alternative explanations.

The primary endpoint wording leaves uncertainty about whether the Cornell Depression Scale, Section D SUM of the Minimum Data Set 3.0, or both were intended as primary measures. The scales have different ranges and descriptions, so their results would require separate identification and interpretation. The record does not report the primary score, change, confidence interval, or analysis result, leaving the outcome itself unevaluable.

The registry reports enrollment of 30 but does not report participant flow, the number with measurements at 16 weeks, or the analysis population. Missing-data handling is not reported in the registry record. These gaps prevent assessment of attrition and of whether available outcome data represent all enrolled participants.

The record also does not report eligibility criteria in detail, baseline score distributions, treatment adherence, dose, or the assessment procedures. The planned approach to multiplicity, the statistical analysis plan, and sample-size justification are not reported in the registry record. Safety information is limited to recorded counts and terms; event timing and relationship to treatment are not reported. Taken together, these omissions restrict both the statistical interpretation of the intended endpoint and the clinical context for the safety entries.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: The Effect on Depressive Symptoms in ECF Residents With COPD — NCT00974246.
• Registry record last updated 2016-12-28; status last verified 2016-11.
• Results first posted 2015-07-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record identifies NCT00974246 as a completed Phase 4, single-group study of open-label Advair Diskus treatment in nursing-home residents with COPD. Enrollment was 30. The recorded study start is 2009-10 and primary completion is 2011-07.

The primary outcome was described as a mean with a 95% confidence interval at 16 weeks, using the Cornell Depression Scale or Section D SUM of the Minimum Data Set 3.0. The record describes both measures but does not report primary outcome values or analysis results. The statistical analysis details, analysis population, and missing-data handling are not reported in the registry record.

The adverse-event entry lists 27 at risk and 3 affected for serious adverse events, and 27 at risk and 27 affected for other adverse events. Three serious-event terms are listed, each with 3.7%. Deaths are not reported in the registry record. The absence of a concurrent comparison and the lack of primary results limit interpretation of both efficacy and safety.